infect
respiratori
mucosa
viral
pathogen
trigger
complex
immunolog
event
affect
host
sought
character
respons
proteom
analysi
nasopharyng
lavag
human
subject
experiment
challeng
influenza
human
rhinoviru
develop
target
assay
measur
peptid
involv
host
respons
allow
classif
acut
respiratori
viru
infect
unbias
proteom
discoveri
analysi
identifi
peptid
correspond
uniqu
protein
reveal
infect
induc
signific
alter
protein
express
includ
protein
involv
acut
inflammatori
respons
innat
immun
respons
complement
cascad
data
provid
insight
natur
biolog
respons
viral
infect
upper
respiratori
tract
protein
dysregul
viral
infect
form
basi
signatur
accur
classifi
infect
state
verif
signatur
use
target
mass
spectrometri
independ
cohort
subject
challeng
influenza
rhinoviru
demonstr
perform
high
accuraci
auroc
tpr
tnr
develop
clinic
diagnost
signatur
may
util
rapid
screen
emerg
infect
avoid
inappropri
antibacteri
therapi
rapid
implement
appropri
therapeut
public
health
strategi
acut
respiratori
viral
arv
infect
among
common
reason
patient
visit
primari
acut
care
set
hong
et
al
johnston
et
al
mani
virus
caus
acut
respiratori
ill
includ
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
influenza
virus
associ
rang
clinic
sever
asymptomat
mild
selflimit
ill
respiratori
failur
death
influenza
alon
caus
million
infect
annual
usa
result
sever
hundr
thousand
hospit
death
thompson
et
al
despit
viral
etiolog
drive
case
acut
respiratori
infect
definit
diagnost
tool
syndrom
lack
even
highli
sensit
pathogenspecif
test
pcr
depend
upon
proper
sampl
techniqu
inclus
virustypespecif
reagent
process
method
moreov
detect
specif
microb
clinic
sampl
necessarili
indic
caus
acut
clinic
syndrom
exampl
report
hrv
detect
asymptomat
individu
byington
et
al
johnston
et
al
therefor
better
tool
help
provid
defin
etiolog
suspect
infecti
syndrom
safe
rapid
accur
costeffect
manner
paramount
import
individu
public
health
recent
note
presidenti
advisori
council
combat
antibioticresist
bacteria
hous
other
oneil
organ
complementari
diagnost
strategi
pathogen
detect
could
focu
util
vari
pathogenclass
specif
hostrespons
infect
ramilo
mejia
zaa
et
al
approach
discrimin
infect
colon
pathogenagnost
therefor
circumv
anoth
limit
pathogen
detect
assay
due
technic
limit
capabl
detect
limit
subset
microorgan
furthermor
categor
infect
base
host
respons
provid
addit
insight
mechan
infect
diseas
respons
may
offer
new
target
pathway
strategi
therapeut
intervent
recent
identifi
gene
express
pattern
peripher
whole
blood
capabl
differenti
zaa
et
al
mcclain
et
al
tsalik
et
al
huang
et
al
individu
symptomat
infect
due
influenza
hrv
rsv
uninfect
individu
accuraci
moreov
arv
signatur
valid
independ
popul
patient
influenza
infect
demonstr
abil
distinguish
bacteri
respiratori
infect
accuraci
healthi
control
accuraci
zaa
et
al
thu
host
deriv
biomark
capabl
make
type
distinct
howev
consid
technic
challeng
inher
develop
peripher
blood
host
gene
express
classifi
diagnost
toolinclud
semiinvas
venipunctur
rna
instabl
process
complex
rel
high
cost
rna
profil
time
resultw
sought
extend
host
respons
paradigm
arv
diagnosi
altern
potenti
suitabl
sampl
matrix
analyt
class
upon
contact
respiratori
epithelium
respiratori
virus
incit
activ
type
interferon
ifn
proinflammatori
cytokin
orchestr
prolifer
inflammatori
cell
innat
immun
respons
regul
induct
adapt
immun
yoneyama
fujita
koyama
et
al
bhoj
et
al
base
promin
role
nasopharyng
epithelium
mediat
arv
infect
hypothes
nasopharyng
lavag
npl
would
reflect
situ
host
respons
serv
potenti
target
diagnost
develop
furthermor
npl
protein
fraction
repres
access
sampl
matrix
provid
highli
tractabl
diagnost
analyt
class
multipl
reaction
monitor
mrm
quantit
mass
spectrometri
ms
platform
facil
develop
multiplex
quantit
assay
measur
specif
protein
level
biolog
fluid
routin
use
biomark
verif
clinic
cohort
kiyonami
et
al
gerszten
et
al
boja
rodriguez
addit
customiz
nearli
target
protein
mrm
assay
provid
specif
quantit
individu
protein
protein
isoform
target
multipl
uniqu
peptid
per
protein
target
combin
intern
stableisotop
label
sil
peptid
standard
assay
match
exceed
quantit
precis
elisa
assay
low
femtomol
limit
quantit
analyt
precis
coeffici
variat
b
across
clinic
size
cohort
addona
et
al
aebersold
et
al
use
human
viral
challeng
cohort
influenza
hrv
discov
independ
verifi
multipl
npl
protein
biomark
capabl
classifi
human
influenza
hrv
infect
uninfect
individu
work
reinforc
import
concept
host
respons
infect
particularli
npl
proteom
serv
potenti
basi
diagnost
test
also
shed
light
complex
interact
host
pathogen
two
common
infecti
diseas
human
pathogen
exposur
approv
relev
institut
review
board
conduct
accord
declar
helsinki
volunt
provid
inform
consent
object
experiment
challeng
studi
gener
clinicomolecular
classifi
arv
infect
develop
character
highdens
sampl
data
set
across
cours
respiratori
viru
exposur
infect
resolut
descript
method
use
challeng
studi
found
supplementari
materi
describ
previous
mcclain
et
al
wood
et
al
zaa
et
al
briefli
healthi
volunt
underw
extens
preenrol
health
screen
exclud
posit
baselin
antibodi
titer
strain
viru
use
challeng
influenza
hrv
serotyp
follow
h
quarantin
instil
viral
inoculum
bilater
nare
subject
use
standard
method
predetermin
interv
biolog
sampl
clinic
symptom
data
collect
npl
sampl
perform
daili
particip
cohort
includ
earli
h
postinocul
oseltamivir
treatment
arm
hrv
includ
blind
sham
inocul
salin
control
group
npl
analys
includ
baselin
time
sampl
individu
challeng
studi
complet
unambigu
symptomatolog
microbiolog
data
avail
npl
sampl
sampl
phenotyp
label
blind
mrm
analysi
assay
manner
ensur
sampl
individu
within
challeng
studi
would
process
batch
assay
close
tempor
proxim
minim
batch
effect
distinct
phenotyp
selfreport
symptom
record
predetermin
interv
prior
inocul
least
twice
daili
throughout
timecours
infect
resolut
report
previous
zaa
et
al
jackson
et
al
describ
supplementari
materi
modifi
jackson
score
requir
subject
rank
symptom
upper
respiratori
infect
headach
sore
throat
rhinorrhea
rhiniti
sneez
cough
myalgia
malais
standard
scale
symptom
high
symptom
symptom
score
tabul
studi
particip
assign
symptom
statu
symptomat
asymptomat
supplementari
tabl
symptomat
subject
time
identifi
time
maxim
symptom
averag
time
defin
cohort
serv
time
chosen
asymptomat
subject
tabl
particip
test
viru
shed
base
quantit
cultur
assay
describ
previous
tabl
descript
experiment
arv
challeng
cohort
four
experiment
hrv
challeng
cohort
two
influenza
two
hrv
describ
includ
adjud
phenotyp
summari
data
individu
discord
symptom
shed
label
ie
symptomat
nonshedd
asymptomat
shedder
shown
sx
symptomat
asx
asymptomat
mean
sx
asx
time
repres
averag
time
maxim
selfreport
symptom
among
subject
includ
npl
analysi
zaa
et
al
outlin
supplementari
tabl
purpos
current
analysi
differenti
symptomat
shed
symptomat
subject
shed
viru
label
infect
asymptomat
nonshedd
uninfect
discord
symptom
shed
statu
reconcil
measur
previous
publish
peripher
blood
gene
express
score
describ
supplementari
materi
tiebreak
gene
express
analysi
gea
repres
host
peripher
blood
respons
viral
infect
supplementari
sampl
collect
subject
cohort
hrv
cohort
describ
previous
zaa
et
al
sampl
cohort
hrv
cohort
collect
process
analyz
similarli
briefli
biolog
sampl
collect
prior
inocul
baselin
predetermin
interv
throughout
cours
infect
resolut
nasopharyng
lavag
procedur
perform
use
steril
salin
solut
ml
nare
describ
supplementari
materi
prior
inocul
interv
postinocul
store
aliquot
studi
focus
comparison
preinocul
baselin
sampl
sampl
taken
shortli
follow
time
npl
sampl
process
proteom
analys
describ
supplementari
materi
pool
discoveri
analysi
four
sampl
pool
creat
repres
four
group
challeng
uninfbl
n
uninft
n
inf
bl
n
inft
n
equal
protein
mass
particip
normal
pool
sampl
individu
particip
sampl
mrm
reduc
alkyl
digest
trypsin
describ
supplementari
materi
prior
analysi
sampl
spike
digest
massprep
standard
water
corpor
intern
technic
standard
unbias
proteom
discoveri
analysi
perform
use
nanoscal
capillari
uplcmsm
describ
supplementari
materi
briefli
quantit
perform
duplic
inject
sampl
pool
provid
accur
mass
intens
abund
acquisit
qualit
identif
result
peptid
fragment
via
search
swissprothuman
www
uniprotorg
databas
also
contain
reversedsequ
decoy
databas
fals
posit
rate
determin
analyt
reproduc
labelfre
method
assess
calcul
variat
measur
abund
spike
standard
demonstr
coeffici
variat
across
eight
inject
quantit
process
peptid
quantiti
across
ten
fraction
sum
dataset
intensitysc
robust
mean
exclud
highest
lowest
detect
featur
across
quantit
acquisit
final
quantit
dataset
npl
base
peptid
contain
uniqu
protein
follow
select
candid
protein
target
unbias
discoveri
data
individu
sampl
subject
target
mrm
assay
detail
supplementari
materi
mrm
assay
develop
transit
select
perform
within
openaccess
skylin
maccoss
laboratori
univ
washington
softwar
initi
five
uniqu
peptid
select
candid
protein
base
averag
precursor
ion
intens
five
transit
precursor
ion
select
base
qualit
dda
discoveri
msm
data
discoveri
dataset
peptid
sequenc
identifi
peptideatla
www
peptideatlasorg
public
repositori
follow
deploy
initi
mrm
assay
healthi
human
control
npl
pool
mrm
method
optim
choos
three
transit
two
robust
peptid
per
protein
custom
sil
peptid
order
candid
peptid
assay
spike
individu
digest
npl
particip
sampl
one
four
ratio
rel
endogen
peptid
describ
supplementari
materi
four
patient
cohort
two
two
hrv
run
individu
run
block
sampl
within
cohort
random
inject
order
across
cohort
singl
mrm
assay
perform
spike
npl
sampl
target
quantiti
oncolumn
four
sampl
prepar
mrm
quantif
attempt
suffici
protein
materi
gener
robust
quantit
data
therefor
exclud
subsequ
analys
assess
analyt
variat
equal
portion
patient
sil
spike
npl
sampl
use
gener
qc
pool
run
approxim
everi
h
across
entir
cohort
addit
sampl
spike
five
sil
peptid
yeastadh
intern
technic
control
mrm
assay
reproduc
metric
shown
supplementari
fig
examin
human
peptid
analyt
plu
yeast
adh
differ
human
protein
eighti
subject
four
viral
challeng
studi
assay
although
four
subject
insuffici
npl
materi
one
time
point
result
sampl
four
peptid
miss
valu
exclud
analysi
miss
valu
zero
sampleanalyt
imput
half
observ
minimum
valu
given
peptid
express
level
remain
peptid
log
transform
carri
forward
analysi
simpl
batch
studi
correct
perform
remov
studywis
mean
valu
peptid
final
analysi
includ
human
peptid
measur
sampl
univari
test
perform
use
twosid
ttest
benjaminihochberg
fdr
correct
pvalu
classif
use
spars
logist
regress
particular
least
absolut
shrinkag
select
oper
lasso
gener
linear
model
binomi
likelihood
friedman
et
al
perform
metric
model
paramet
obtain
via
nest
leaveoneout
crossvalid
loocv
classif
perform
metric
consid
area
receiv
oper
curv
auroc
fawcett
true
posit
rate
tpr
true
neg
rate
tnr
protein
peptid
relax
classifi
rather
subject
pathway
associ
analysi
use
david
function
annot
tool
huang
da
et
al
use
uniprot
access
identifi
human
background
dataset
gener
analyz
current
studi
avail
correspond
author
reason
request
comput
script
written
matlab
use
glmnet
toolbox
webstanfordeduhastieglmnetmatlab
access
http
bitbucketorgrhenaonplebm
four
independ
viral
challeng
studi
conduct
tabl
two
challeng
influenza
two
hrv
describ
previous
wood
et
al
zaa
et
al
clinic
selfreport
symptom
data
along
correspond
sampl
collect
multipl
time
per
day
across
cours
exposur
infect
resolut
challeng
particip
standard
algorithm
appli
assign
phenotyp
label
describ
symptomat
shed
infect
statu
supplementari
tabl
respect
across
timecours
sinc
symptom
shed
statu
alway
congruent
requir
present
defin
patient
infect
absent
subject
label
uninfect
discord
appli
tiebreak
base
gene
express
analysi
gea
repres
host
peripher
blood
respons
viral
infect
supplementari
tabl
unpublish
data
n
arzouni
burk
mcclain
hero
challeng
particip
includ
analysi
half
particip
adjud
becom
infect
infect
hrv
hrv
overview
proteom
discoveri
candid
biomark
verif
strategi
depict
fig
despit
readili
access
matrix
one
technic
challeng
studi
npl
variabl
protein
yield
subject
subject
overcom
limit
util
twophas
biomark
discoveri
strategi
first
phase
use
pool
npl
sampl
singl
challeng
indepth
msbase
discoveri
proteom
assist
identif
priorit
candid
biomark
second
phase
target
assay
develop
candid
use
sensit
quantit
reproduc
mrm
approach
verif
util
marker
perform
origin
three
independ
challeng
cohort
use
target
mrm
quantit
discoveri
proteom
perform
challeng
cohort
use
openplatform
liquid
chromatographi
tandem
ms
analysi
four
set
pool
npl
sampl
uninfect
infect
individu
baselin
time
maxim
symptom
time
use
equal
protein
mass
per
particip
sampl
across
four
uniqu
npl
sampl
pool
total
peptid
correspond
uniqu
protein
identifi
peptidelevel
fals
discoveri
rate
fdr
next
investig
variabl
express
npl
protein
infect
uninfect
viral
challeng
pool
sampl
three
criteria
use
priorit
suitabl
peptid
subsequ
mrm
quantif
entir
collect
identifi
npl
protein
supplementari
tabl
first
sought
minimum
twofold
chang
express
baselin
time
infect
pool
least
peptid
per
protein
criterion
use
classifi
protein
would
increas
decreas
function
infect
within
individu
time
level
protein
increas
least
twofold
protein
decreas
least
twofold
baselin
time
second
criterion
greater
twofold
differ
infect
timematch
uninfect
subject
criteria
enabl
specif
protein
compar
test
control
subject
time
symptom
present
includ
protein
higher
express
protein
lower
express
third
criterion
exclud
protein
might
reflect
gener
nasal
trauma
stem
repeat
collect
address
calcul
express
chang
time
maxim
symptom
infect
subject
inft
rel
similar
time
uninfect
subject
uninft
priorit
candid
uniqu
respons
infect
time
addit
four
protein
met
criteria
also
report
associ
infect
zaa
et
al
inflamm
pirillo
et
al
includ
verif
phase
base
criteria
protein
select
subsequ
mrm
assay
develop
increas
decreas
express
infect
particip
mrm
quantit
lcmsm
method
util
synthet
sil
peptid
intern
standard
provid
absolut
specif
target
analyt
rel
abund
measur
kiyonami
et
al
addona
et
al
total
uniqu
peptid
mrm
assay
design
target
two
uniqu
peptid
priorit
candid
biomark
protein
plu
human
serum
albumin
fig
studi
design
experiment
workflow
twophas
strategi
employ
identifi
character
candid
protein
biomark
arv
infect
npl
sampl
collect
particip
four
experiment
arv
challeng
cohort
phase
discoveri
analysi
four
npl
pool
prepar
cohort
analyz
use
unbias
number
subject
n
sampl
includ
pool
shown
uninf
uninfect
individu
inf
infect
individu
bl
baselin
time
maxim
symptom
phase
origin
three
addit
independ
challeng
cohort
assay
target
mrm
quantit
peptid
express
data
individu
total
sampl
use
deriv
npl
arv
classifi
classif
perform
assess
independ
challeng
cohort
use
loocv
yeast
alcohol
dehydrogenas
spike
exogen
control
two
protein
yield
singl
peptid
suitabl
mrm
assay
statherin
one
viabl
sil
peptid
could
synthes
filaggrin
one
two
sil
peptid
insolubl
third
protein
calcyphosin
yield
third
suitabl
peptid
assay
publicli
avail
peptideatla
databas
follow
develop
mrm
assay
perform
individu
npl
sampl
subject
across
four
viral
challeng
studi
cohort
includ
origin
influenza
cohort
second
cohort
two
hrv
challeng
cohort
hrv
origin
set
human
peptid
assay
design
peptid
repres
protein
success
measur
cohort
observ
direct
magnitud
chang
protein
express
consist
initi
pool
discoveri
measur
fig
target
mrm
peptid
measur
fig
expect
sinc
pool
sampl
biolog
averag
sampl
includ
pool
exampl
retino
acid
receptor
respond
protein
measur
across
three
uniqu
peptid
pool
discoveri
data
set
averag
fold
chang
uninfect
infect
time
target
mrm
assay
develop
two
peptid
demonstr
averag
increas
express
assay
individu
npl
sampl
tabl
similarli
two
complement
factor
b
cfab
peptid
display
increas
express
assay
individu
sampl
mrm
compar
increas
sum
cfab
protein
composit
assay
pool
discoveri
dataset
also
expect
pool
discoveri
dataset
show
much
narrow
standard
deviat
fig
deviat
due
technic
variabl
wherea
variabl
target
mrm
experi
individu
fig
abl
discern
actual
biolog
variat
combin
result
provid
confid
pooledsampl
phase
discoveri
strategi
give
good
measur
averag
protein
express
level
situat
matrix
interest
extrem
samplelimit
phase
target
mrm
assay
reproduc
protein
express
chang
candid
select
use
pool
data
also
provid
biolog
varianc
higher
sensit
sought
independ
verifi
candid
peptid
express
chang
individu
particip
sampl
second
challeng
cohort
well
two
addit
challeng
studi
use
second
common
arv
human
rhinoviru
individu
particip
npl
sampl
addit
cohort
process
measur
use
panel
experiment
control
peptid
mrm
assay
deriv
cohort
combin
analysi
across
four
independ
arv
cohort
found
median
samplewis
peptid
express
intens
rel
constant
across
sampl
regardless
infect
statu
though
peptid
analyt
measur
differenti
express
benjaminihochberg
fdr
b
time
maxim
symptom
infect
subject
likewis
peptid
analyt
differenti
express
benjaminihochberg
fdr
b
hrv
subject
time
peptid
overlap
two
two
hrv
cohort
direct
magnitud
chang
peptid
analyt
hrv
significantli
differenti
express
either
hrv
cohort
highli
correl
r
viral
group
fig
indic
analyt
like
viru
typespecif
use
differenti
hrv
find
provid
basi
investig
util
protein
assay
multianalyt
classif
model
arv
infect
build
npl
protein
classifi
distinguish
infect
uninfect
subject
util
lasso
spars
logist
regress
friedman
et
al
build
list
potenti
logist
regress
model
classifi
train
discrimin
sampl
infect
individu
time
inft
pair
baselin
measur
infbl
uninfect
individu
time
uninft
fig
show
perform
npl
classif
model
select
peptid
uniqu
protein
four
independ
challeng
cohort
includ
discord
individu
adjud
use
gea
statu
tiebreak
analysi
ignor
pair
natur
sampl
train
classif
task
order
better
estim
accuraci
situat
baselin
sampl
avail
overal
classifi
perform
fig
loocv
yield
auroc
ci
bootstrap
k
sampl
tpr
tnr
baselin
sampl
asymptomat
cohort
withheld
model
train
sinc
phenotyp
model
tri
identifi
howev
repres
cohort
asymptomat
individu
avail
valid
appli
model
tabl
candid
biomark
protein
rel
express
ratio
row
repres
host
npl
protein
mrm
assay
develop
uniprot
gene
symbol
protein
name
shown
candid
protein
number
peptid
measur
unbias
pool
target
mrm
analys
unbias
pool
ratio
shown
select
criteria
describ
supplementari
tabl
fold
express
chang
bl
infect
individu
measur
peptidespecif
mrm
assay
across
four
arv
challeng
studi
shown
twosid
ttest
benjaminihochberg
fdradjust
pvalu
parenthes
peptid
respect
sampl
reveal
one
misclassif
error
loocv
confus
matrix
ident
peptid
classifi
weight
shown
tabl
b
respect
also
perform
analys
separ
infect
statu
individu
independ
gea
statu
ie
includ
symptomat
shedder
asymptomat
shedder
surprisingli
increas
tabl
b
respect
classif
perform
loocvauc
vs
individu
use
shed
outcom
ignor
symptom
loocvauc
experiment
design
hrv
challeng
includ
sham
inocul
control
group
fig
panel
hrv
green
sever
particip
receiv
intranas
inocul
salin
without
hrv
four
seven
sham
control
report
symptom
suffici
classifi
symptomat
despit
receiv
hrv
inoculum
show
microbiolog
evid
infect
four
subject
classifi
neg
npl
mrm
analysi
consist
absenc
hrv
shed
observ
gea
host
respons
blood
mrna
arv
infect
pathway
huang
et
al
wood
et
al
mcclain
et
al
subject
sinc
classifi
test
fig
includ
uniqu
protein
repeat
analysi
use
relax
variabl
select
paramet
better
describ
biolog
pathway
involv
lasso
regular
paramet
rather
new
classifi
nearli
ident
perform
auroc
tpr
tnr
select
peptid
uniqu
protein
pathway
associ
analysi
perform
use
david
function
annot
tool
huang
da
et
al
use
protein
select
expand
classifi
inform
differenti
infect
uninfect
individu
result
supplementari
tabl
signific
annot
cluster
primarili
driven
protein
cfab
associ
gene
ontolog
go
biolog
process
term
acut
inflammatori
respons
p
innat
immun
respons
p
inflammatori
respons
p
defens
respons
p
similar
result
seen
expand
queri
includ
protein
candid
use
phase
mrm
analys
conduct
unbias
target
protein
analys
human
npl
sampl
collect
four
independ
arv
challeng
cohort
two
influenza
two
hrv
defin
host
protein
express
pattern
characterist
respons
viral
respiratori
infect
result
demonstr
robust
chang
secret
protein
occur
npl
infect
individu
subset
protein
capabl
accur
classifi
infect
state
individu
despit
chang
assay
approach
method
transit
pool
phase
discoveri
unbias
proteom
individu
measur
phase
discoveri
mrm
observ
good
reproduct
direct
magnitud
peptid
express
measur
method
provid
confid
specif
quantit
perform
method
importantli
approach
enabl
accur
select
candid
biomark
pool
phase
discoveri
sampl
amount
sever
limit
individu
sampl
preclud
abil
analyz
sampl
use
unbias
though
biomark
candid
attrit
expect
biolog
varianc
avail
pool
data
appropri
strateg
filter
candid
abl
high
success
rate
statist
valid
phase
pool
discoveri
phase
individu
mrm
measur
investig
group
other
shown
differenti
express
host
gene
rna
level
peripher
blood
respons
arv
infect
ramilo
et
al
zaa
et
al
wood
et
al
zaa
et
al
heavi
represent
gene
ifnsign
canon
pathway
innat
immun
respons
signal
analysi
differenti
express
npl
protein
infect
individu
demonstr
involv
sever
biolog
pathway
critic
mount
host
defens
viru
infect
includ
innat
immun
respons
acut
inflammatori
respons
defens
respons
pathway
inclus
three
member
complement
system
cfab
particularli
consist
innat
immun
respons
complement
system
enhanc
abil
antibodi
phagocyt
cell
clear
pathogen
infect
site
ricklin
et
al
despit
appar
relat
pathway
involv
appear
extens
overlap
differenti
express
nasal
protein
identifi
challeng
studi
previou
peripher
blood
rna
signatur
arv
infect
character
challeng
cohort
zaa
et
al
one
gene
product
increas
npl
peptid
peripher
blood
rna
level
upon
influenza
infect
cameron
et
al
cameron
et
al
zaa
et
al
gene
also
call
peptidas
inhibitor
belong
serpin
superfamili
import
role
innat
immun
modul
classic
pathway
complement
activ
gaboriaud
et
al
complement
system
potenti
damag
host
tissu
complement
control
protein
must
tightli
regul
activ
bind
complement
protein
inhibit
activ
classic
complement
pathway
thu
discoveri
fit
well
understand
biolog
diseas
notabl
absent
npl
protein
analysi
proinflammatori
cytokin
chemokin
gene
product
previous
shown
strong
contributor
host
respons
peripher
blood
near
site
arv
infect
kimura
et
al
oshanski
colleagu
assay
nasal
lavag
sampl
cohort
healthi
naturallyinfect
influenza
patient
use
multiplex
cytokin
chemokin
assay
panel
report
correl
inflammatori
cytokin
diseas
progress
oshanski
et
al
aptamerbas
detect
method
subsequ
use
screen
cohort
gener
quantit
measur
protein
analyt
nasal
lavag
show
differenti
express
protein
includ
cytokin
associ
immun
respons
infect
marion
et
al
identifi
tabl
classif
model
perform
classifi
perform
individu
sampl
four
arv
cohort
repres
loocv
confus
matrix
b
ident
contribut
weight
peptid
amino
acid
sequenc
onelett
notat
averag
peptid
length
amino
acid
rang
residu
neg
weight
valu
indic
downregul
upon
infect
inflammatori
cytokin
differenti
express
pool
npl
analysi
possibl
cytokin
protein
npl
sampl
express
level
detect
limit
lcmsbase
method
coupl
target
method
capabl
detect
quantifi
cytokin
directli
may
provid
enhanc
dataset
biomark
discoveri
inclus
sham
infect
particip
hrv
cohort
provid
import
opportun
assess
accuraci
standard
clinic
symptom
assess
diagnosi
arv
infect
clinic
definit
symptomat
even
appli
standard
symptom
score
algorithm
includ
element
subject
thu
may
imperfect
describ
infect
find
despit
appar
presenc
symptom
infect
mrm
analysi
classifi
seven
individu
uninfect
suggest
npl
biomark
assay
lower
fals
posit
rate
diagnos
hrv
infect
standard
symptom
statu
measur
experiment
challeng
studi
provid
excel
model
studi
arv
infect
ill
prescreen
volunt
known
time
exposur
standard
pathogen
exposur
extens
sampl
data
collect
cours
ill
howev
experiment
challeng
perfectli
replic
natur
arv
infect
ill
human
volunt
studi
young
healthi
repres
rel
homogen
popul
contrast
patient
present
clinic
care
demograph
heterogen
varieti
comorbid
present
variou
time
cours
ill
contain
far
greater
breadth
potenti
pathogen
beyond
two
studi
addit
valid
perform
divers
popul
patient
present
clinic
care
communityonset
diseas
generaliz
studi
find
requir
addit
valid
high
tnr
suggest
assay
may
provid
valu
rule
arv
infect
categor
infect
base
upon
host
respons
repres
emerg
strategi
great
potenti
complement
current
pathogenbas
diagnost
well
provid
addit
insight
pathobiolog
infect
result
present
studi
provid
evid
proteinbas
host
respons
arv
infect
detect
nasopharyng
space
respons
involv
perturb
pathway
involv
acut
inflamm
innat
immun
respons
work
demonstr
target
assay
measur
peptid
involv
respons
allow
classif
arv
infect
high
degre
accuraci
valid
find
across
independ
experiment
infect
influenza
human
rhinoviru
cohort
suggest
robust
gener
respons
viral
infect
develop
clinic
diagnost
signatur
may
util
rapid
screen
emerg
infect
avoid
inappropri
antimicrobi
therapi
rapid
implement
appropri
therapeut
public
health
strategi
nonetheless
valid
biomark
addit
valid
communitybas
cohort
import
demonstr
potenti
util
assay
clinic
applic
furthermor
test
approach
across
larger
seri
upper
respiratori
virus
import
understand
full
potenti
util
limit
assay
combin
host
protein
biomark
nasal
viral
antigen
detect
may
quit
valuabl
clinic
care
optim
therapeut
decis
make
whilst
posit
result
assay
may
avoid
use
inappropri
microbi
therapi
like
requir
vigil
part
clinician
exclud
bacteri
coinfect
clinic
indic
previou
demonstr
potenti
host
responsebas
presymptomat
detect
infect
use
blood
rna
express
rais
intrigu
possibl
npl
protein
host
respons
assay
might
use
earli
detect
arv
infect
evalu
avail
proteom
signatur
accur
classifi
arv
infect
might
migrat
simpl
inexpens
antibodybas
test
routin
use
clinic
laboratori
overthecount
diagnost
applic
repres
import
advanc
may
one
day
yield
arv
host
respons
test
safe
simpl
rapid
inexpens
accur
fund
support
work
provid
us
defens
advanc
research
project
agenc
darpa
contract
elt
mtm
support
award
number
respect
clinic
scienc
research
develop
servic
va
offic
research
develop
funder
role
prepar
manuscript
